Yongxin Zhang is the General Manager (CEO) for Zyxell Inc, USA. He is also doing collaborative research work with 7-Hill Pharmaceutical Inc. (Houston), Texas Heart Institute (Houston) and Southwestern Medical Center (Dallas) for hematopoietic stem cell transplantation; Halsa Pharmaceutical Inc. (Houston) and Agennex Inc. for Anti-cancer drug evaluation; Gradalis Inc. (Dallas) for the immunological evaluation of cancer vaccine; SinoStem LLC (Nanjing) for Bioreactor development and 4th Junyi University (Chongqing) for stem cell expansion. He has completed his MD from Beijing Medical College, China in the year 1983. He has received his Ph.D from Beijing Medical College, China in the year 1989. After that he has continued his postdoc training at Baylor College of Medicine during 1996-2004. Dr. Zhang has published numerous papers in reputed journals and has participated in several international conferences. He is serving as editor and reviewer for several international journals.
Immunology of cancer and infectious diseases. Immune evasion of cancer cells and cancer immunotherapy. Development and evaluation of new vaccines. Effects of apoptosis on immune system. Impact of aging on immunity. IgA and mucosal immunology.
Studies on cell (including stem cells), tissue and organ transplantation, graft against host, immunosuppression as well as immunotolerance in cell transplantation; molecular mechanism of the tissue construction and the “self-renewal” maintenance in expanding stem cells; Stem cell and immunocyte expansion. Bio-reactor development.
Preparation, purification and conjugation of monoclonal antibodies; Development and commercialization of new immunoassays and molecular biologic assays (including rapid HLA typing assay) for clinical application.
Study of immunological and molecular biologic mechanisms of acute and chronic infection using immunological, molecular biologic, microbiologic, pathologic, epidemic and statistical methods.
Study of structure and function of genes and proteins with the technique of gene cloning and expression as well as Crispr/Cas9 gene edition, gene knockout and gene transfection.
Diagnosis, treatment and prevention of cancer, infectious diseases, and liver diseases.
Animal models: Virus infection mouse model and surgically-induced liver failure rat model.